David Meeker

Board advisor. Dr. Meeker is the President and CEO of Rhythm Pharmaceuticals and previously KSQ Therapeutics. He spent 17 years at Genzyme from being a Medical Director to Senior Vice President and later became the Business Unit leader for Genzyme’s Lysosomal Storage Disease and Thyrogen programs in Europe. Dr. Meeker was promoted to be the President of the Global LSD business unit where he oversaw the global launches of Aldurazyme, Fabrazyme and Myozyme. Prior to Genzyme, he was the Director of the Pulmonary Critical Care at the Cleveland Clinic and an Assistant professor of medicine at Ohio State University. Dr. Meeker received his M.D. from the University of Vermont Medical School and completed Internal Medicine residency at Beth Israel Hospital and a Pulmonary/Critical Care fellowship at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.